Meet the Steering Committee

Meeting the Need benefits from the involvement of a group of esteemed addiction-treatment professionals. This multidisciplinary team provides guidance and insight on the development of select content and materials for this website.

Genie Bailey Genie L. Bailey, M.D.

American Board of Addiction Medicine
Clinical Associate Professor of Psychiatry and Human Behavior
Warren Alpert Medical School of Brown University
Distinguished Life Fellow
American Psychiatry Association
Director of Research
Director of Medications for Addiction Division
Stanley Street Treatment and Resources
Fall River, MA
Laura P. Bamford, MD, MSCE Laura P. Bamford, M.D., M.S.C.E.

Medical Director
Clinica Bienestar
Staff Physician
Jonathon Lax Treatment Center
Clinical Assistant Professor of Medicine
Perelman School of Medicine University of Pennsylvania
Philadelphia, PA
Jeffrey A. Berman, M.D., D.F.A.S.A.M. Jeffrey A. Berman, M.D., D.F.A.S.A.M.

Clinical Assistant Professor of Psychiatry
Department of Psychiatry
Rutgers Robert Wood Johnson
Medical School
Medical Director
Department of Addiction Psychiatry
SOBA College Recovery
New Brunswick, NJ
Tim Fong, M.D. Tim Fong, M.D.

Professor of Psychiatry
Department of Psychiatry
Professor of Psychiatry
Department of Addiction Psychiatry
University of California,
Los Angeles
Los Angeles, CA
Linda J. Frazier, R.N., M.C.H.E.S. Linda J. Frazier, M.A., R.N., M.C.H.E.S.

Director of Addictions Initiatives
Advocates for Human Potential Inc. (AHP)
Sudbury, MA
Thomas R. Kosten, M.D. Thomas R. Kosten, M.D.

Waggoner Chair and Professor of Psychiatry
Department of Psychiatry
Baylor College of Medicine
Division of Addictions
VA Medical Center
Houston, TX
Laura G. Leahy, P.M.H.-C.N.S./F.N.P., B.C. Laura G. Leahy, Dr.N.P., A.P.R.N., F.A.A.N.P.

Board Certified Psychiatric & Addictions Advanced Practice Nurse
Master Clinician in Psychopharmacology
Fellow in the American Association of Nurse Practitioners
APNSolutions, LLC
Sewell, NJ
Paolo Mannelli, M.D. Paolo Mannelli, M.D.

Associate Professor
Department of Psychiatry and Behavioral Sciences
Duke University
Associate Medical Director
Division of Addiction
Duke Addictions Program
Durham, NC
Brian OConnor Brian W. O’Connor, M.D.

Middlesex Recovery, P.C.
Woburn, MA

Consultants are paid by Alkermes.



Genie L. Bailey, M.D., is a consultant or on advisory boards for Alkermes, Inc., Braeburn Pharmaceuticals, and BioDelivery Sciences International, Inc. (BDSI). She is on the speaker bureau for Alkermes, Indivior PLC, and BDSI. She has received non-financial support from Indivior (medication for study and travel costs) and Alkermes (travel costs). Her institution has received grant support from Braeburn Pharmaceuticals and Indivior.

Laura P. Bamford, M.D., M.S.C.E., is a consultant for Alkermes, Inc., and is on the speaker bureau. She has received research support from Janssen Pharmaceuticals, Inc.

Jeffrey A. Berman, M.D., D.F.A.S.A.M., is a consultant for Alkermes, Inc. He serves or has served on the speaker bureaus for Alkermes, Sunovion Pharmaceuticals Inc., and Otsuka Pharmaceutical Co., Ltd.

Tim Fong, M.D., is a consultant for Alkermes, Inc., and for Onward Method, Inc. He is on the speaker bureau for Indivior PLC. Dr Fong has received research support from Constellation Behavioral Health.

Linda J. Frazier, M.A., R.N., M.C.H.E.S., is a NIATx consultant for materials development and training. She is also a consultant for Alkermes, Inc.

Thomas R. Kosten, M.D., is a consultant for Alkermes, Inc.; Neurocrine Biosciences, Inc.; Novartis Pharmaceuticals Corporation; and Purdue Pharma L.P. He receives research support from Alkermes.

Laura G. Leahy, Dr.N.P., A.P.R.N., F.A.A.N.P., is a consultant for Alkermes, Inc. and the Shire Nurse Advisory Board. She is on the speaker bureau for Alkermes, Genomind, and NEOS Therapeutics, Inc. She has also been an author/editor for American Psychiatric Association Publishing (Manual of Clinical Psychopharmacology for Nurses, 2013).

Paolo Mannelli, M.D., is a consultant for Alkermes, Inc., and Guidepoint Global. He has received research support from Alkermes and Orexo AB (publ).

Brian W. O’Connor, M.D., is a consultant for Alkermes, Inc. He is also on the speaker bureau for Alkermes.

See Important Safety Information for VIVITROL below. See Prescribing Information and Medication Guide. Review Medication Guide with your patients.

(naltrexone for extended-release injectable suspension)


VIVITROL is indicated for:

  • Treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL. Patients should not be actively drinking at the time of initial VIVITROL administration.
  • Prevention of relapse to opioid dependence, following opioid detoxification.
  • VIVITROL should be part of a comprehensive management program that includes psychosocial support.


VIVITROL is contraindicated in patients:

  • Receiving opioid analgesics
  • With current physiologic opioid dependence
  • In acute opioid withdrawal
  • Who have failed the naloxone challenge test or have a positive urine screen for opioids
  • Who have exhibited hypersensitivity to naltrexone, polylactide-co-glycolide (PLG), carboxymethylcellulose, or any other components of the diluent


Vulnerability to Opioid Overdose:

  • After opioid detoxification, patients are likely to have a reduced tolerance to opioids. VIVITROL blocks the effects of exogenous opioids for approximately 28 days after administration. As the blockade wanes and eventually dissipates completely, use of previously tolerated doses of opioids could result in potentially life-threatening opioid intoxication (respiratory compromise or arrest, circulatory collapse, etc.).
  • Cases of opioid overdose with fatal outcomes have been reported in patients who used opioids at the end of a dosing interval, after missing a scheduled dose, or after discontinuing treatment. Patients and caregivers should be told of this increased sensitivity to opioids and the risk of overdose.
  • Although VIVITROL is a potent antagonist with a prolonged pharmacological effect, the blockade produced by VIVITROL is surmountable. The plasma concentration of exogenous opioids attained immediately following their acute administration may be sufficient to overcome the competitive receptor blockade. This poses a potential risk to individuals who attempt, on their own, to overcome the blockade by administering large amounts of exogenous opioids.
  • Any attempt by a patient to overcome the VIVITROL blockade by taking opioids may lead to fatal overdose. Patients should be told of the serious consequences of trying to overcome the opioid blockade.

Injection Site Reactions:

  • VIVITROL injections may be followed by pain, tenderness, induration, swelling, erythema, bruising, or pruritus; however, in some cases injection site reactions may be very severe.
  • Injection site reactions not improving may require prompt medical attention, including, in some cases, surgical intervention.
  • Inadvertent subcutaneous/adipose layer injection of VIVITROL may increase the likelihood of severe injection site reactions.
  • Select proper needle size for patient body habitus, and use only the needles provided in the carton.
  • Patients should be informed that any concerning injection site reactions should be brought to the attention of their healthcare provider.

Precipitation of Opioid Withdrawal:

  • When withdrawal is precipitated abruptly by administration of an opioid antagonist to an opioid-dependent patient, the resulting withdrawal syndrome can be severe. Some cases of withdrawal symptoms have been severe enough to require hospitalization, and in some cases, management in the ICU.
  • To prevent occurrence of precipitated withdrawal, opioid-dependent patients, including those being treated for alcohol dependence, should be opioid-free (including tramadol) before starting VIVITROL treatment:
    • An opioid-free interval of a minimum of 7–10 days is recommended for patients previously dependent on short-acting opioids.
    • Patients transitioning from buprenorphine or methadone may be vulnerable to precipitated withdrawal for as long as two weeks.
  • If a more rapid transition from agonist to antagonist therapy is deemed necessary and appropriate by the healthcare provider, monitor the patient closely in an appropriate medical setting where precipitated withdrawal can be managed.
  • Patients should be made aware of the risk associated with precipitated withdrawal and be encouraged to give an accurate account of last opioid use.


  • Cases of hepatitis and clinically significant liver dysfunction have been observed in association with VIVITROL. Warn patients of the risk of hepatic injury; advise them to seek help if experiencing symptoms of acute hepatitis. Discontinue use of VIVITROL in patients who exhibit acute hepatitis symptoms.

Depression and Suicidality:

  • Alcohol- and opioid-dependent patients taking VIVITROL should be monitored for depression or suicidal thoughts. Alert families and caregivers to monitor and report the emergence of symptoms of depression or suicidality.

When Reversal of VIVITROL Blockade Is Required for Pain Management:

  • For VIVITROL patients in emergency situations, suggestions for pain management include regional analgesia or use of non-opioid analgesics. If opioid therapy is required to reverse the VIVITROL blockade, patients should be closely monitored by trained personnel in a setting staffed and equipped for CPR.

Eosinophilic Pneumonia:

  • Cases of eosinophilic pneumonia requiring hospitalization have been reported. Warn patients of the risk of eosinophilic pneumonia and to seek medical attention if they develop symptoms of pneumonia.

Hypersensitivity Reactions:

  • Patients should be warned of the risk of hypersensitivity reactions, including anaphylaxis.

Intramuscular Injections:

  • As with any IM injection, VIVITROL should be administered with caution to patients with thrombocytopenia or any coagulation disorder.

Alcohol Withdrawal:

  • Use of VIVITROL does not eliminate nor diminish alcohol withdrawal symptoms.


  • Serious adverse reactions that may be associated with VIVITROL therapy in clinical use include severe injection site reactions, eosinophilic pneumonia, serious allergic reactions, unintended precipitation of opioid withdrawal, accidental opioid overdose, and depression and suicidality.
  • The adverse events seen most frequently in association with VIVITROL therapy for alcohol dependence (ie, those occurring in ≥5% and at least twice as frequently with VIVITROL than placebo) include nausea, vomiting, injection site reactions (including induration, pruritus, nodules, and swelling), muscle cramps, dizziness or syncope, somnolence or sedation, anorexia, decreased appetite or other appetite disorders.
  • The adverse events seen most frequently in association with VIVITROL in opioid-dependent patients (ie, those occurring in ≥2% and at least twice as frequently with VIVITROL than placebo) were hepatic enzyme abnormalities, injection site pain, nasopharyngitis, insomnia, and toothache.

You are encouraged to report side effects to the FDA. Visit or call 1-800-FDA-1088.

See Prescribing Information and Medication Guide.